Skip to main content
NCBI home page
Springer logoLink to Springer
. 2019 Jan 19;39(1):115. doi: 10.1007/s40261-019-00747-y

Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study

Sermsiri Sangroongruangsri 1, Usa Chaikledkaew 1,✉, Suthasinee Kumluang 2, Olivia Wu 3, Claudia Geue 3, Tanapat Ratanapakorn 4, Pattara Leelahavarong 2, Lily Ingsrisawang 5, Paisan Ruamviboonsuk 6, Wongsiri Taweebanjongsin 7, Janejit Choovuthayakorn 8, Apichart Singalavanija 9, Prut Hanutsaha 10, Kittisak Kulvichit 11, Thitiporn Ratanapojnard 12, Warapat Wongsawad 7, Yot Teerawattananon 2
PMCID: PMC6827997  PMID: 30659496

Correction to: Clinical Drug Investigation (2018) 38:853–865 10.1007/s40261-018-0678-5

The Open Access license, which previously read:

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Should read:

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article has been corrected.

Articles from Clinical Drug Investigation are provided here courtesy of Springer

RESOURCES